Background: Medullary thyroid cancer (MTC) comprises only 4% of all thyroid cancers and originates from the parafollicular C-cells. HIF-1 alpha expression has been implied as an indicator of worse prognosis in various solid tumors. However, whether expression of HIF-1 alpha is a prognosticator in MTC remained unclear. Our aim was to evaluate the prognostic value of HIF-1 alpha in patients with MTC.
Methods: All patients with MTC who were operated on between 1988 and 2014 in five tertiary referral centers in The Netherlands were included. A tissue microarray was constructed in which 111 primary tumors could be analyzed for expression of HIF-1 alpha, CAIX, Glut-1, VEGF and CD31 and correlated with clinicopathologic variables and survival.
Results: The mean age of patients was 46.3 years (SD 15.6), 59 (53.2%) were male. Of the 111 primary tumors, 49 (44.1%) were HIF-1 alpha negative and 62 (55.9%) were HIF-1 alpha positive. Positive HIF-1 alpha expression was an independent negative indicator for progression free survival (PFS) in multivariate cox regression analysis (HR 3.1; 95% CI 1.3 - 7.3). Five-years survival decreased from 94.0% to 65.9% for the HIF-1 alpha positive group (p= 0.007). Even within the group of patients with TNM-stage IV disease, HIF-1 alpha positivity was associated with a worse prognosis, shown by a decrease in 5-years survival of 88.0% to 49.3% ( p= 0.020).
Conclusion: Expression of HIF-1 alpha is strongly correlated with adverse prognosis of MTC. This could open up new ways for targeted systemic therapy of MTC.
- medullary thyroid cancer
- hypoxia inducible factor 1 alpha
- tissue microarray
- HYPOXIA-INDUCIBLE FACTOR-1
- ANTIGEN DOUBLING-TIMES
- TISSUE MICROARRAYS